ClinicalTrials.gg
Active, not recruitingNCT07288398LEVEL-2Updated Oct 15, 2026

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

A Phase 3 interventional study of TNX-103 and Placebo in Pulmonary Hypertension Associated With HFpEF, sponsored by Tenax Therapeutics, Inc.. Active, not recruiting at 140 sites in 15 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Tenax Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Now Active, not recruiting1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
236th of 1,601
540 · median 65
Started
2026
with 94 others
Phase 3
147 of 2,157
21 open now
Primary completion
2028-06
later than 311 of 436 live
Registered
2,078th of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 236th largest by planned enrollment of the 1,601 interventional ones that give a count, is one of 95 that started in 2026, is one of 147 in phase 3, reaches primary completion later than 311 of the 436 other live ones, and was the 2,078th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) as measured by the change in 6-Minute Walk Distance.

Read the detailed description

Approximately 540 participants will be randomized in a 2:1 ratio to receive an oral dose of levosimendan or placebo. Participants will be eligible for an open label extension (OLE) of 52-weeks.

03

Conditions studied

  • Pulmonary Hypertension Associated With HFpEF

Browse trials for

Keywords

  • PH-HFpEF
  • levosimendan
  • HFpEF
  • Heart Failure
  • Pulmonary Hypertension Group 2
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women, ≥18 to 85 years of age
  2. Class II or III or ambulatory NYHA Class IV symptoms
  3. A diagnosis of World Health Organization (WHO) Group 2 PH-HFpEF with qualifying hemodynamics verified by right heart catheterization (RHC)
  4. A qualifying baseline RHC
  5. A qualifying echocardiogram
  6. A qualifying 6-MWD
  7. A 48-hour ambulatory cardiac rhythm monitor during the Screening Period
  8. Requirements related to child bearing potential, , and egg/sperm donation)

Exclusion criteria

Exclusion Criteria:

  1. A diagnosis of PH WHO Groups 1, 3, 4, or 5
  2. Echocardiographic evidence for hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy
  3. Structural heart repair or replacement of the aortic valve or mitral valve (surgical or percutaneous) OR, planned valve intervention OR, the presence of significant valve disease
  4. A diagnosis of pre-existing lung disease
  5. History of severe allergic or anaphylactic reaction or to the in the product
  6. Major surgery within 60 days
  7. Prior heart, lung, or heart-lung transplants or of \<12 months
  8. History of other diseases that may limit or complicate participation in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo (oral)

    Drug: Placebo

  • Active comparator
    TNX-103

    Oral levosimendan

    Drug: TNX-103

Interventions

  • Oral levosimendan

  • DrugPlacebo

    Matching placebo (oral)

06

What researchers measure

Primary outcomes

  1. 6-Minute Walk Distance (6MWD)

    Change in 6-minute walk distance

    Time frame: 26 weeks

Secondary outcomes

  1. KCCQ (Kansas City Cardiomyopathy Questionnaire) score is a standardized measure that ranges from 0 to 100, where a higher score indicates better health.

    Change in KCCQ Total Symptom Score

    Time frame: 26 weeks

  2. Clinical Worsening Events

    Number of Clinical Worsening Events

    Time frame: 26 weeks

  3. Clinical Worsening Event

    Time to first occurrence of a Clinical Worsening Event

    Time frame: 26 weeks

  4. NYHA (New York Heart Association) classification assesses and categorizes a patient's physical ability and symptoms into four classes, the lower the classification, the least impact on physical activity.

    Change in NYHA Functional Class

    Time frame: 26 weeks

07

Study locations

140 sites
  • Tenax Investigational Site
    Alexander City, Alabama 35010, United States
  • Tenax Investigational Site
    Tucson, Arizona 85724, United States
  • Tenax Investigational Site
    Sacramento, California 95816, United States
  • Tenax Investigational Site
    San Francisco, California 94143, United States
  • Tenax Investigational Site
    Stanford, California 94305-5208, United States
  • Tenax Investigational Site
    Torrance, California 90502, United States
  • Tenax Investigational Site
    Athens, Georgia 30606, United States
  • Tenax Investigational Site
    Atlanta, Georgia 30322, United States
  • Tenax Investigational Site
    Chicago, Illinois 60611-4494, United States
  • Tenax Investigational Site
    Chicago, Illinois 60637, United States
  • Tenax Investigational Site
    Mount Prospect, Illinois 60056, United States
  • Tenax Investigational Site
    Peoria, Illinois 61636, United States
  • Tenax Investigational Site
    Indianapolis, Indiana 46260, United States
  • Tenax Investigational Site
    New Orleans, Louisiana 70115-6969, United States
  • Tenax Investigational Site
    West Monroe, Louisiana 71291, United States
  • Tenax Investigational Site
    Boston, Massachusetts 02114-2621, United States
  • Tenax Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Tenax Investigational Site
    Ypsilanti, Michigan 48197, United States
  • Tenax Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Tenax Investigational Site
    Rochester, Minnesota 55905, United States
  • Tenax Investigational Site
    Kansas City, Missouri 64111, United States
  • Tenax Investigational Site
    St Louis, Missouri 63136, United States
  • Tenax Investigational Site
    Omaha, Nebraska 68198, United States
  • Tenax Investigational Site
    Reno, Nevada 89502, United States
  • Tenax Investigational Site
    New York, New York 10021, United States
  • Tenax Investigational Site
    New York, New York 10032, United States
  • Tenax Investigational Site
    Rochester, New York 14617, United States
  • Tenax Investigational Site
    Durham, North Carolina 27710, United States
  • Tenax Investigational Site
    Winston-Salem, North Carolina 27101, United States
  • Tenax Investigational Site
    Cleveland, Ohio 44195-0001, United States
  • Tenax Investigational Site
    Columbus, Ohio 43210, United States
  • Tenax Investigational Site
    Allentown, Pennsylvania 18105, United States
  • Tenax Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
  • Tenax Investigational Site
    Wynnewood, Pennsylvania 19096-3450, United States
  • Tenax Investigational Site
    Charleston, South Carolina 29425, United States
  • Tenax Investigational Site
    Nashville, Tennessee 37205, United States
  • Tenax Investigational Site
    Austin, Texas 78705, United States
  • Tenax Investigational Site
    Dallas, Texas 75390, United States
  • Tenax Investigational Site
    El Paso, Texas 79905-2707, United States
  • Tenax Investigational Site
    Houston, Texas 77030-2342, United States
  • Tenax Investigational Site
    Charlottesville, Virginia 22908, United States
  • Tenax Investigational Site
    Norfolk, Virginia 23507-1904, United States
  • Tenax Investigational Site
    Seattle, Washington 98122, United States
  • Tenax Investigational Site
    Madison, Wisconsin 53706, United States
  • Tenax Investigational Site
    Marshfield, Wisconsin 54449, United States
  • Tenax Investigational Site
    San Juan Bautista, Buenos Aires 1888, Argentina
  • Tenax Investigational Site
    Buenos Aires, Buenos Aires F.D. 1280, Argentina
  • Tenax Investigational Site
    Buenos Aires, C1180AAX, Argentina
  • Tenax Investigational Site
    Buenos Aires, C1428ART, Argentina
  • Tenax Investigational Site
    Corrientes, W3400AMZ, Argentina
  • Tenax Investigational Site
    Córdoba, 5000, Argentina
  • Tenax Investigational Site
    Córdoba, X5016KET, Argentina
  • Tenax Investigational Site
    San Luis, D5702JRS, Argentina
  • Tenax Investigational Site
    Santa Fe, S2002KDS, Argentina
  • Tenax Investigational Site
    Vienna, State of Vienna 1090, Austria
  • Tenax Investigational Site
    Braunau am Inn, 5280, Austria
  • Tenax Investigational Site
    Graz, 8036, Austria
  • Tenax Investigational Site
    Klagenfurt, 9020, Austria
  • Tenax Investigational Site
    Sankt Pölten, 3100, Austria
  • Tenax Investigational Site
    Vienna, 1100, Austria
  • Tenax Investigational Site
    Salvador, Estado de Bahia 40170-130, Brazil
  • Tenax Investigational Site
    Goiânia, Goiás 74605, Brazil
  • Tenax Investigational Site
    Belo Horizonte, Minas Gerais 30220, Brazil
  • Tenax Investigational Site
    Curitiba, Paraná 80215-901, Brazil
  • Tenax Investigational Site
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Tenax Investigational Site
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Tenax Investigational Site
    Ribeirão Preto, São Paulo 14026-020, Brazil
  • Tenax Investigational Site
    Burgas, 8000, Bulgaria
  • Tenax Investigational Site
    Pleven, 5800, Bulgaria
  • Tenax Investigational Site
    Sofia, 1309, Bulgaria
  • Tenax Investigational Site
    Sofia, 1407, Bulgaria
  • Tenax Investigational Site
    Sofia, 1431, Bulgaria
  • Tenax Investigational Site
    Sofia, 1750, Bulgaria
  • Tenax Investigational Site
    Ostrava, 72880, Czechia
  • Tenax Investigational Site
    Prague, 10034, Czechia
  • Tenax Investigational Site
    Prague, 15006, Czechia
  • Tenax Investigational Site
    Le Kremlin-Bicêtre, 94270, France
  • Tenax Investigational Site
    Montpellier, 34295, France
  • Tenax Investigational Site
    Nantes, 44007, France
  • Tenax Investigational Site
    Nice, 06001, France
  • Tenax Investigational Site
    Pau, 64000, France
  • Tenax Investigational Site
    Poitiers, 86000, France
  • Tenax Investigational Site
    Bad Bevensen, 29549, Germany
  • Tenax Investigational Site
    Bad Nauheim, 61231, Germany
  • Tenax Investigational Site
    Berlin, 12683, Germany
  • Tenax Investigational Site
    Dresden, 01307, Germany
  • Tenax Investigational Site
    Hamburg, 20251, Germany
  • Tenax Investigational Site
    Jena, 07747, Germany
  • Tenax Investigational Site
    Mainz, 55131, Germany
  • Tenax Investigational Site
    Budapest, 1122, Hungary
  • Tenax Investigational Site
    Budapest, 1134, Hungary
  • Tenax Investigational Site
    Debrecen, 4032, Hungary
  • Tenax Investigational Site
    Szeged, 6275, Hungary
  • Tenax Investigational Site
    Acquaviva delle Fonti, 70021, Italy
  • Tenax Investigational Site
    Bergamo, 24127, Italy
  • Tenax Investigational Site
    Messina, 98125, Italy
  • Tenax Investigational Site
    Milan, 20132, Italy
  • Tenax Investigational Site
    Milan, 20138, Italy
  • Tenax Investigational Site
    Milan, 20149, Italy
  • Tenax Investigational Site
    Pavia, 27100, Italy

Showing the first 100 of 140 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2028, 27 months after the start.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's planned 27 months is below that.

Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 17, 2025
StartActual
Mar 3, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Sites
1 site removed
Show 1 removed
  • Tenax Investigational Site · Houston, United States
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • Tenax Investigational Site · Houston, United States
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07288398
Lead sponsor
Tenax Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
Mar 3, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TNX-103

Start the discussion